Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21838223 | 0.90 | MDM4 (0.48) | TNFMDM4TP53SLC17A5TLR2 | |
| SCHEMBL21838225 | 0.90 | MDM4 (0.48) | TNFMDM4TP53SLC17A5TLR2 | |
| SCHEMBL12118786 | 0.90 | MDM4 (0.48) | TNFMDM4TP53SLC17A5TLR2 | |
| SCHEMBL30889963 | 0.90 | MDM4 (0.48) | TNFMDM4TP53SLC17A5TLR2 | |
| SCHEMBL29477061 | 0.90 | MDM4 (0.48) | TNFMDM4TP53SLC17A5TLR2 | |
| SCHEMBL16616142 | 0.87 | MDM4 (0.49) | TNFMDM4TP53SLC17A5TLR2 | |
| SCHEMBL8145837 | 0.84 | TNF (0.44) | TNFHDAC1HDAC2IDO1MDM4 | |
| SCHEMBL28404544 | 0.83 | CASP3 (0.43) | TLR2KMT2A | |
| SCHEMBL28404541 | 0.83 | CASP3 (0.43) | TLR2KMT2A | |
| SCHEMBL25657764 | 0.83 | TLR2 (0.49) | TNFMDM4TP53SLC17A5TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956296-B2 | Compounds containing a vascular disrupting agent | INCANTHERA LTD (GB) | 2018-05-01 | — | — | US | disclosed |
| US-9937267-B2 | Methods of treating cancer using compounds containing a vascular disrupting agent | INCANTHERA LTD (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20170266307-A1 | Methods Of Treating Cancer Using Compounds Containing A Vascular Disrupting Agent | ELLIPSES PHARMA LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20160243252-A1 | COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT | ELLIPSES PHARMA LIMITED (GB) | 2016-08-25 | — | — | US | disclosed |
| US-20160243252-A1 | COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT | ELLIPSES PHARMA LIMITED (GB) | 2016-08-25 | — | — | US | disclosed |
| US-9358303-B2 | Compounds containing a vascular disrupting agent | INCANTHERA LTD (GB) | 2016-06-07 | — | — | US | disclosed |
| US-9358303-B2 | Compounds containing a vascular disrupting agent | INCANTHERA LTD (GB) | 2016-06-07 | — | — | US | disclosed |
| US-20150196658-A1 | Compounds | Incanthera Ltd. | 2015-07-16 | — | — | US | disclosed |
| US-20150196658-A1 | Compounds | Incanthera Ltd. | 2015-07-16 | — | — | US | disclosed |
| US-8927486-B2 | Compounds | INCANTHERA LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-8927486-B2 | Compounds | INCANTHERA LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-20140179592-A1 | Compounds | INCANTHERA LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179592-A1 | Compounds | INCANTHERA LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20110275554-A1 | COMPOUNDS | THE UNIVERSITY OF BRADFORD (GB) | 2011-11-10 | — | — | US | disclosed |
| US-20100168036-A1 | GROWTH FACTOR | UNIVERSITY OF BRADFORD (GB) | 2010-07-01 | — | — | US | disclosed |
| WO-2010046628-A1 | COMPOUNDS | UNIVERSITY OF BRADFORD (GB) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196658-A1 | Compounds | ADAM17, MMP3, MMP25 | TNF 3565/4885HDAC1 780/4885HDAC2 1311/4885 |
| US-20170266307-A1 | Methods Of Treating Cancer Using Compounds Containing A Vascular Disrupting Agent | MMP10, MMP25, MMP26 | TNF 3363/4885HDAC1 468/4885HDAC2 812/4885 |
| US-20160243252-A1 | COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT | MMP10, MMP11, MMP3 | TNF 3314/4885HDAC1 658/4885HDAC2 1514/4885 |
| US-20110275554-A1 | COMPOUNDS | ADAM17, MMP3, MMP25 | TNF 3565/4885HDAC1 780/4885HDAC2 1311/4885 |
| US-20100168036-A1 | GROWTH FACTOR | HDGF, VEGFA, PGF | TNF 226/4885HDAC1 1368/4885HDAC2 2700/4885 |
| US-20140179592-A1 | Compounds | MMP9, MMP3, MMP10 | TNF 2683/4885HDAC1 498/4885HDAC2 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.